Health ❯ Healthcare ❯ Clinical Trials

Obesity Treatment

Semaglutide Orforglipron Weight Loss Medications Weight Loss Drugs GLP-1 Receptor Agonists Aleniglipron Retatrutide Survodutide Petrelintide CagriSema Phase 3 Trials Eli Lilly Trials Ozempic Cagrilintide Wegovy WVE-007 Efficacy Studies Novo Nordisk Medication Effectiveness CT-388 Orforglipron Study Phase 3 Studies

3 ARTICLES

2mo ago

Veru Rally Follows Novo Nordisk Deal to Supply Wegovy for Phase 2b Trial

The no-cost drug supply and Novo’s first negotiation rights are being read as validation of Veru’s plan to pair enobosarm with semaglutide to protect muscle during GLP‑1 weight loss.

6 ARTICLES

3mo ago

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

5 ARTICLES

4mo ago

Wave Life Sciences Shares Plunge 30% After Early Obesity Trial Readout

6 ARTICLES

4mo ago

Structure’s Oral Obesity Pill Delivers 16.3% Placebo-Adjusted Weight Loss in Phase 2

9 ARTICLES

6mo ago

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

6 ARTICLES

10mo ago

Phase 3 Trials Show Greater Weight Loss With 7.2 mg Injection and 25 mg Oral Semaglutide

3 ARTICLES

10mo ago

Triple-Dose Semaglutide Outperforms Standard Regimen in Weight-Loss Trials